

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
IKARIA ACQUISITION INC.	05/14/2010
IKARIA, INC.	05/14/2010
IKARIA RESEARCH, INC.	05/14/2010
INO THERAPEUTICS, LLC	05/14/2010
IKARIA INTERNATIONAL, INC.	05/14/2010
IKARIA THERAPEUTICS LLC	05/14/2010
IKARIA DEVELOPMENT SUBSIDIARY ONE LLC	05/14/2010
IKARIA DEVELOPMENT SUBSIDIARY TWO LLC	05/14/2010

RECEIVING PARTY DATA

Name:	CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
Street Address:	11 MADISON AVENUE
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10010

PROPERTY NUMBERS Total: 33

Property Type	Number
Patent Number:	5417950
Patent Number:	5670125
Patent Number:	5670127
Patent Number:	5692495
Application Number:	10129147
Application Number:	10416883
Application Number:	10444074
Application Number:	60249765
Application Number:	10416870

OP \$1320.00 5417950

Application Number:	60781036
Application Number:	60783450
Application Number:	60849900
Application Number:	60868778
Application Number:	60877051
Application Number:	60885619
Application Number:	60896727
Application Number:	11684968
Application Number:	60944444
Application Number:	12664872
Application Number:	12520772
Application Number:	12023840
Application Number:	12690368
Application Number:	61146222
Application Number:	12580458
Application Number:	61303532
Application Number:	61309973
Application Number:	12494598
PCT Number:	US0866973
PCT Number:	US0788402
PCT Number:	US1021562
PCT Number:	US0961046
PCT Number:	US0904526
PCT Number:	US0145519

CORRESPONDENCE DATA

Fax Number: (866)826-5420
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 301-638-0511
Email: ipresearchplus@comcast.net
Correspondent Name: IP Research Plus, Inc.
Address Line 1: 21 Tadcaster Circle
Address Line 2: attn: Penelope J.A. Agodoa
Address Line 4: Waldorf, MARYLAND 20602

ATTORNEY DOCKET NUMBER:	35849
NAME OF SUBMITTER:	Penelope J.A. Agodoa

Total Attachments: 36

source=35849#page1.tif
source=35849#page2.tif
source=35849#page3.tif
source=35849#page4.tif
source=35849#page5.tif
source=35849#page6.tif
source=35849#page7.tif
source=35849#page8.tif
source=35849#page9.tif
source=35849#page10.tif
source=35849#page11.tif
source=35849#page12.tif
source=35849#page13.tif
source=35849#page14.tif
source=35849#page15.tif
source=35849#page16.tif
source=35849#page17.tif
source=35849#page18.tif
source=35849#page19.tif
source=35849#page20.tif
source=35849#page21.tif
source=35849#page22.tif
source=35849#page23.tif
source=35849#page24.tif
source=35849#page25.tif
source=35849#page26.tif
source=35849#page27.tif
source=35849#page28.tif
source=35849#page29.tif
source=35849#page30.tif
source=35849#page31.tif
source=35849#page32.tif
source=35849#page33.tif
source=35849#page34.tif
source=35849#page35.tif
source=35849#page36.tif

PATENT SECURITY AGREEMENT dated as of May 14, 2010 (this "**Agreement**"), among Ikaria, Inc. ("**Holdings**"), Ikaria Acquisition Inc. (the "**Borrower**"), the subsidiaries of the Borrower listed on Schedule I hereto (the "**Subsidiary Parties**") and Credit Suisse AG, Cayman Islands Branch, as Collateral Agent (in such capacity, the "**Collateral Agent**").

Reference is made to (a) the Guarantee and Collateral Agreement dated as of 14, 2010 (as amended, amended and restated, supplemented or otherwise modified from time to time, the "**Security Agreement**"), among Holdings, the Borrower, the Lenders party thereto and the Collateral Agent and (b) the Credit Agreement dated as of 14, 2010 (as amended, amended and restated, supplemented or otherwise modified from time to time, the "**Credit Agreement**"), among Holdings, the Borrower, the Lenders party thereto and Credit Suisse AG, Cayman Islands Branch, as administrative agent (in such capacity, the "**Administrative Agent**") and Collateral Agent. The Lenders have agreed to extend credit to the Borrower subject to the terms and conditions set forth in the Credit Agreement. The obligations of the Lenders to extend such credit are conditioned upon, among other things, the execution and delivery of this Agreement. Holdings and the Subsidiary Parties are affiliates of the Borrower, will derive substantial benefits from the extension of credit to the Borrower pursuant to the Credit Agreement and are willing to execute and deliver this Agreement in order to induce the Lenders to extend such credit. Accordingly, the parties hereto agree as follows:

SECTION 1. Terms. Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Security Agreement. The rules of construction specified in Section 1.02 of the Credit Agreement also apply to this Agreement.

SECTION 2. Grant of Security Interest. As security for the payment or performance, as the case may be, in full of the Obligations, each Grantor, pursuant to the Security Agreement, did and hereby does grant to the Collateral Agent, its successors and assigns, for the benefit of the Secured Parties, a security interest in, all right, title or interest in or to any and all of the following assets and properties now owned or at any time hereafter acquired by such Grantor or in which such Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the "**Patent Collateral**"):

all letters patent of the United States or the equivalent thereof in any other country, all registrations and recordings thereof, and all applications for letters patent of the United States or the equivalent thereof in any other country, including registrations, recordings and pending applications in the United States Patent and Trademark Office or any similar offices in any other country, including those listed on Schedule II (the "**Patents**"), and all reissues, continuations, divisions, continuations-in-part, renewals or extensions thereof, and the inventions disclosed or claimed therein, including the right to make, use and/or sell the inventions disclosed or claimed therein.


SECTION 3. Security Agreement. The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the Patent Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern (and for the avoidance of doubt, any assets excluded from Article 9 Collateral pursuant to Section 4.01 of the Security Agreement shall not be part of the Patent Collateral).

[Remainder of this page intentionally left blank]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.


IKARIA, INC.,

by


Name: Daniel Tasse
Title: Chairman and Chief Executive Officer

IKARIA ACQUISITION INC.,

by


Name: Daniel Tasse
Title: President


IKARIA RESEARCH, INC.,

by


Name: Daniel Tasse
Title: President


INO THERAPEUTICS, LLC,

by


Name: Daniel Tasse
Title: President and Chief Executive Officer

IKARIA INTERNATIONAL, INC.,

by


Name: Daniel Tasse
Title: President


[[3210402]]

Signature Page to Ikaria Patent Security Agreement

PATENT
REEL: 024588 FRAME: 0624

IKARIA THERAPEUTICS LLC,

by



Name: Daniel Tassé

Title: President

IKARIA DEVELOPMENT SUBSIDIARY
ONE LLC

by



Name: Daniel Tassé

Title: President

IKARIA DEVELOPMENT SUBSIDIARY
TWO LLC

by



Name: Daniel Tassé

Title: President


[[3210402]]

Signature Page to Ikaria Patent Security Agreement


PATENT
REEL: 024588 FRAME: 0625

CREDIT SUISSE AG, CAYMAN
ISLANDS BRANCH, as Collateral Agent,

by


Name: JOHN D. TORONTO
Title: DIRECTOR

by


Name: VIPUL DHADDA
Title: ASSOCIATE

[[3210402]]

Signature Page to Ikaria Patent Security Agreement

PATENT
REEL: 024588 FRAME: 0626

Schedule I

<u>Subsidiary Parties</u>
Ikaria Research, Inc.
INO Therapeutics, LLC
Ikaria International, Inc.
Ikaria Therapeutics LLC
Ikaria Development Subsidiary One LLC
Ikaria Development Subsidiary Two LLC

Schedule II

I. Patents

A. Patents and Patent applications Owned by INO Therapeutics LLC

Title	Filing Date	Type	Number
Compositions and Methods of Enhancing Survivability and Reducing Injury of Cells, Tissues, Organs and Organisms under Hypoxic or Ischemic Conditions	March 10, 2006	Provisional (P1)	60/781,036
Compositions and Methods of Enhancing Survivability and Reducing Injury of Cells, Tissues, Organs and Organisms under Hypoxic or Ischemic Conditions	March 17, 2006	Provisional (P2)	60/783,450
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2006	Filed Provisional (P1)	60/849,900
Compositions and Methods of Enhancing Survivability and Reducing Injury of Cells, Tissues, Organs, and Organisms Under Ischemic or Hypoxic Conditions	December 6, 2006	Filed Provisional	60/868,778
Combinations of Nitric Oxide and Sulfide and Methods of Use and Manufacture Thereof	December 22, 2006	Filed Provisional	60/877,051
Methods, Compositions and Articles of Manufacture for Enhancing Survivability of Cells, Tissues, Organs, and Organisms	January 18, 2007	Filed Provisional	60/885,619
Liquid Chalcogenide Compositions and Manufacturing Using the Same	March 23, 2007	Filed Provisional (P2)	60/896,727
Compositions and Methods of Enhancing Survivability and Reducing Injury of Cells, Tissues, Organs, and Organisms Under Ischemic or Hypoxic Conditions	March 12, 2007	US Utility	11/684,968
Compositions and Methods to Modulate Angiogenesis	June 15, 2007	Filed Provisional	60/944,444
Compositions and Methods to Modulate Angiogenesis	June 15, 2008	US Utility	12/664,872
Compositions and Methods to Modulate Angiogenesis	June 15, 2008	PCT	PCT/US2008/066973
Combinations of Nitric Oxide and Sulfide and Methods of Use and Manufacture Thereof	December 20, 2007	PCT	PCT/US2007/088402
Combinations of Nitric Oxide and Sulfide and Methods of Use and Manufacture Thereof	December 20, 2007	US Utility	12/520,772
Compositions Comprising Sulfide Alone or In Combination With Nitric Oxide and Their Use	June 13, 2008	Japanese National Phase of PCT	010-512395

		US08/066973	
Combinations of Nitric Oxide and Sulfide and Methods of Use and Manufacture Thereof	June 13, 2008	European National Phase of PCT US08/066973	8771066.1
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	US Utility	12/023,840
Compositions and Methods to Modulate Angiogenesis	June 15, 2008	PCT	PCT/US/08/066973
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Singapore National Phase of PCT (WO2008/043081)	200901916-7
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	New Zealand National Phase of PCT (WO2008/043081)	575671
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Canadian National Phase of PCT (WO2008/043081)	2,664,341
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Australian National Phase of PCT (WO2008/043081)	2007303050
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	European National Phase of PCT (WO2008/043081)	078553810.5
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Brazilian National Phase of PCT (WO2008/043081)	496109
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Indonesia National Phase of PCT (WO2008/043081)	W-00200900884
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Japanese National Phase of PCT (WO2008/043081)	2009-531630
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Israel National Phase of PCT (WO2008/043081)	197945
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Mexican National Phase of PCT (WO2008/043081)	MX/A/2009/03741
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Indian National Phase of PCT (WO2008/043081)	2741/DELNP/2009
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	South Korean National Phase of PCT	10-2009-7009278

		(WO2008/043081)	
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Chinese National Phase of PCT (WO2008/043081)	20078004115 7.7
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Hong Kong	09110449.7
Methods for Treating or Preventing Radiocontrast Agent Induced Kidney Injury	January 21, 2010	US Utility	12/690,368
Methods for Treating or Preventing Radiocontrast Agent Induced Kidney Injury	January 21, 2010	PCT	PCT/US10/215 62
Compositions and Methods for Treating or Preventing Hypoxic or Ischemic Injury	October 16, 2008	Provisional	61/146,222
Compositions and Methods for Treating or Preventing Hypoxic or Ischemic Injury	October 16, 2009	PCT	PCT/US2009/ 061046
Compositions and Methods for Treating or Preventing Hypoxic or Ischemic Injury	October 16, 2009	US Utility	12/580,458
Compositions and Methods for Treating or Preventing Hypoxic or Ischemic Injury	Feb. 11, 2010	Provisional	61/303,532
Process for the Manufacture of High Purity Carbon Monoxide	March 3, 2010	Provisional	61/309,973
Methods of Treating Term and Near-Term Neonates Having Hypoxic Respiratory Failure Associated with Clinical or Echocardiographic Evidence of Pulmonary Hypertension	June 30, 2009	US Utility	12/494,598
Methods of Treating Term and Near-Term Neonates Having Hypoxic Respiratory Failure Associated with Clinical or Echocardiographic Evidence of Pulmonary Hypertension	June 30, 2009	Australia	2009202685
Methods of Treating Term and Near-Term Neonates Having Hypoxic Respiratory Failure Associated with Clinical or Echocardiographic Evidence of Pulmonary Hypertension	June 30, 2009	Canada	2671029
Methods of Treating Term and Near-Term Neonates Having Hypoxic Respiratory Failure Associated with Clinical or Echocardiographic Evidence of Pulmonary Hypertension	June 30, 2009	Japan	2009-157623
Methods of Treating Term and Near-Term Neonates Having Hypoxic Respiratory Failure Associated with Clinical or Echocardiographic Evidence of Pulmonary Hypertension	June 30, 2009	Europe	09251949.5
Methods of Treating Term and Near-Term Neonates Having Hypoxic	June 30, 2009	Mexico	N/A

Respiratory Failure Associated with Clinical or Echocardiographic Evidence of Pulmonary Hypertension			
Devices and Methods for Engaging Indexed Valve and Pressurized Canister Assembly with Collar and for Linear Actuation by Plunger Assembly into Fluid Communication	June 27, 2009	PCT	PCT/US2009/4526

Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue/ Pub Date
1	United States	271,688	7 July 1994	5,417,950	23 May 1995
	Australia	0020189	22 May 1995	693875	9 July 1998
	Singapore	0000548	31 May 1995	28281	1 April 1996
	South Korea	0019759	6 July 1995	0161607	16 Nov 1998
	Japan	0172125	7 July 1995	8057242	5 March 1996
	Canada	2149835	19 May 1995	2149835	8 Jan 1996
	South Africa	04572	2 June 1995	9504572	29 Mar 1996
	2	United States	533,121	15 Sep 1995	5,670,125
3	United States	533,821	26 Sep 1995	5,670,127	23 Sep 1997
	Australia	0065771	20 Sep 1996	704026	15 April 1999
	Canada	2183027	9 Aug 1996	2183027	27 Mar 1997
	Europe*	0306853	20 Sep 1996	0788999	13 Aug 1997
	Japan	0252569	25 Sep 1996	9175804	8 July 1997
	South Korea	0042498	25 Sep 1996	100196886	15 June 1999
	Philippines	199653916	14 Aug 1996	1199653916	24 March 2000
	South Africa	0006983	16 Aug 1996	9606983	24 Feb 1997
4	United States	626,413	2 April 1996	5,692,495	2 Dec 1997
	Australia	0016239	11 Mar 1997	710642	9 Oct 1997
	Canada	2198557	26 Feb 1997	2198557	3 Oct 1997
	Europe*	0302198	27 Mar 1997	0799793	8 Oct 1997
	Japan	1997124229	14 May 1997	10314309	02 Dec 1998
	Philippines	199755505	06 Feb 1997	1199755505	07 Mar 2000
	South Korea	0012047	1 April 1997	203721	15 June 1999
	South Africa	0002770	1 April 1997	9702770	24 Oct 1997

* Europe listing intended to include any applications filed in designated countries.

Family	Country	Filing date	Application Number	Patent Number	Status	Grant Date
*1	Argentina	2 November 2000	P000105779		in examination	
	Australia	2 November 2000	1745601	AU 778347	granted/ registered	2 December 2004
	Brazil	2 November 2000	PI0015329		in examination	
	Canada	2 November	2,389,655		filed	

Family	Country	Filing date	Application Number	Patent Number	Status	Grant Date
		2000				
	Chile	2 November 2001	2991-2000		1st office action	
	China	2 November 2000	00815287.X	CN 815287	granted/ registered	7 December 2005
	Czech Republic	2 November 2000	PV20021559		in examination	
	Germany	2 November 2000	60022070.2	EP 1225913 B1	granted/ registered	17 August 2005
	Estonia	2 November 2000	P200200240		filed	
	Spain	2 November 2000	00980159.8	EP 1225913 B1	granted/ registered	17 August 2005
	France	2 November 2000	00980159.8	EP 1225913 B1	granted/ registered	17 August 2005
	Great Britain	2 November 2000	00980159.8	EP 1225913 B1	granted/ registered	17 August 2005
	Italy	2 November 2000	00980159.8	EP 1225913 B1	granted/ registered	17 August 2005
	Japan	2 November 2000	2001-534406		filed	17 August 2005
	Mexico	2 November 2000	2002004069		filed	
	Norway	2 November 2000	20022113		filed	
	Poland	2 November 2000	P354653		filed	
	Sweden	2 November 2000	00980159.8	EP 1225913 B1	granted/ registered	17 August 2005
	Singapore	2 November 2000	200202170-7	SG 88376	granted/ registered	30 July 2004
	United States	2 November 2000	10/129,147		2nd office action	
	South Africa	2 November 2000	20023391	ZA 20023391	granted/ registered	26 February 2003
*2	Argentina	14 November 2001	P010105331		in examination	
	Australia	15 November 2001	2002214519	AU 2002214519	granted/ registered	26 November 2004
	Canada	15 November 2001	2429224		filed	
	Chile	15 November 2001	2765-2001		2nd office action	
	China	15 November	01820894.0		in	

Family	Country	Filing date	Application Number	Patent Number	Status	Grant Date
		2001			examination	
	Czech Republic	15 November 2001	PV2003-1617		in examination	
	Estonia	15 November 2001	P200300226		filed	
	EPO	15 November 2001	01983064.5	1339428	to be granted	
	Israel	15 November 2001	155968		filed	
	Japan	15 November 2001	2002-542424		in examination	
	New Zealand	15 November 2001	526295	NZ 526295	granted/ registered	10 February 2005
	Poland	15 November 2001	P362023		filed	
	Slovak Republic	15 November 2001	PV0731-2003		in examination	
	United States	15 November 2001	10/416,883		filed	
	South Africa	15 November 2001	20033845	ZA 20033845	granted/ registered	24 November 2004
*3	Australia	2 April 2004	PCT/SE2004/000511		filed	
	Canada	2 April 2004	2,521,052		filed	
	Chile	2 April 2004	0722-2004		filed	
	China	2 April 2004	03146249.9		filed	
	EPO	2 April 2004	04725572.4-2107	1608405	filed	
	Japan	2 April 2004	2006-508000		filed	
	Mexico	2 April 2004	PCT/SE2004/000511		filed	
	United States	23 May 2003	10/444,074		filed	

(i) Patents and Patent Applications Co-Owned by INO Therapeutics and VenTek LLC

Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue / Pub Date
1	United States	60/249765	17 Nov 2000	N/A	N/A
	United States	10/416870	15 Nov 2001	2004/0045608	11 Mar 2004
	PCT	PCT/US01/45519	15 Nov 2001	WO 02/40914	23 May 2002

	Europe	2001/0991983	15 Nov 2001	1356228	29 Oct 2003
	Australia	2002/0032458	15 Nov 2001	3245802	27 May 2002
	Canada	2429203	15 Nov 2001	2429203	23 May 2002
	Japan	2002/0542799	15 Nov 2001	514846	20 May 2004
	Mexico	2003/PA04329	16 May 2003	03004329	1 July 2005

B. Patents and Patent Applications Licensed by INO Therapeutics LLC

Licensed From Datex-Ohmeda					
Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue /Pub Date
1	United States	156175	22 Nov 1993	5,558,083	24 Sep 1996
	Australia	74407/94	4 Oct 1994	683918	27 Nov 1997
	Japan	1994/0287969	22 Nov 1994	7194705	8 Jan 1995
	Canada	2133516	23 May 1995	2133516	18 Dec 2001
	Europe	94308533.2	18 Nov 1994	0659445	28 June 1995
	Austria	94308533.2	18 Nov 1994	192661	15 May 2000
	Germany	1994/6024386	18 Nov 1994	69424386	15 June 2000
	New Zealand	264571	29 Sept 2004	264571	22 Aug 1997
	Spain	94308533.2	18 Nov 1994	2147771	1 Oct 2000
	South Africa	19947680	30 Sept 1994	199407680	24 April 1996
2	United States	620063	21 Mar 1996	5,699,790	23 Dec 1997
	Canada	2196129	28 Jan 1997	2196129	21 Sept 1997
	Europe	97301895.5	20 Mar 1997	0796632	13 May 1998
	Germany	1997/6019392	20 Mar 1997	69719392	10 April 2003
	Japan	199768004	21 Mar 1997	10015069	20 Jan 1998
	Spain	97301895.5	20 Mar 1997	2194155	16 Nov 2003
3	United States	766834	13 Dec 1996	5,732,694	31 Mar 1998
	Europe	1997304891	04 July 1997	818212	14 Jan 1998
	Canada	2206477	29 May 1997	2206477	10 Jan 1998
4	United States	766833	13 Dec 1996	5,732,693	31 Mar 1998
	Europe	1997307696	30 Sept 1997	834332	08 April 1998
	Canada	2212180	30 July 1997	2212180	02 April 1998
5	United States	764596	13 Dec 1996	5,752,504	19 May 1998
	Europe	1997307697	30 Sept 1997	839546	06 May 1998
	Canada	2211748	30 July 1997	2211748	02 April 1998

Licensed From Datex-Ohmeda (Higenbottam)					
Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue /Pub Date
1	United States	624613	3 July 1996	5,839,433	24 Nov 1998
	PCT	PCT/GB94/02229	11 Oct 1994	95/10315	20 April 1995
	Europe	1994/0928978	11 Oct 1994	0723466	31 July 1996
	Austria	1994/0078199	11 Oct 1994	7819994	4 May 1995

	Germany	1994/6012502	11 Oct 1994	6941250	17 Sep 1998
	Spain	1994/0928978	11 Oct 1994	2123833	16 Jan 1999
	UK	1994/20504.4	11 Oct 1994	2283179	5 Mar 1995

Licensed From Beth Israel Deaconess Medical Center, et al

Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue /Pub Date
1	United States	10/177930	21 June 2002	2003/0039638	27 Feb 2003
	United States	11/401722	10 April 2006	N/A	N/A
	Australia	2002318377	21 June 2002	N/A	N/A
	Bulgaria	108492	21 June 2002	N/A	N/A
	Brazil	PI0210599-3	21 June 2002	N/A	N/A
	Canada	2451266	21 June 2002	N/A	N/A
	China	2816344.3	21 June 2002	CN 1545548A	10 Nov 2004
	Czech Republic	PV 2003-3448	21 June 2002	1211-4197	12 May 2004
	Europe	02747932.8	21 June 2002	1404811	7 April 2004
	Hong Kong	04107560.1	21 June 2002	1067380	8 April 2005
	Hungary	P0400371	21 June 2002	N/A	N/A
	Indonesia	W00200400116	21 June 2002	038924	8 April 2004
	India	02163/DELNP/03	21 June 2002	N/A	N/A
	Japan	2002-506568	21 June 2002	N/A	N/A
	South Korea	10-2003-7016702	21 June 2002	N/A	N/A
	Mexico	PA/2003/012031	21 June 2002	N/A	N/A
	Norway	2003 5637	21 June 2002	N/A	N/A
	New Zealand	530671	21 June 2002	N/A	N/A
	Philippines	1-2003-501340	21 June 2002	N/A	N/A
	Poland	P-367544	21 June 2002	N/A	N/A
	Russia	2004101410	21 June 2002	N/A	N/A
	Singapore	200307663-5	21 June 2002	N/A	N/A
	Singapore	200601852-7	21 Mar 2002	N/A	N/A
	Slovak Republic	PP 1594-2003	21 June 2002	1594-2003	3 Aug 2004
	PCT	PCT/US02/19687	21 June 2002	WO 03/000114	3 Jan 2003
	South Africa	2003/09828	21 June 2002	N/A	N/A
2	United States	09/538788	30 Mar 2000	N/A	N/A
	United States	10/053535	15 Jan 2002	2002/0155166	24 Oct 2002
	Australia	2002308676	9 May 2002	N/A	N/A
	Bosnia/Herzegovina	BAP041865A	9 May 2002	N/A	N/A
	Brazil	PI0215717-9	9 May 2002	N/A	N/A
	Canada	2484770	9 May 2002	N/A	N/A
	China	02829299.5	9 May 2002	CN 1638781A	13 July 2005
	Columbia	04123506	9 May 2002	1383	31 Mar 2006
	Serbia/	P969/2004	9 May 2002	N/A	N/A

Licensed From Beth Israel Deaconess Medical Center, et al					
Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue /Pub Date
	Montenegro				
	Eurasia	200401478	9 May 2002	N/A	N/A
	Europe	02807413.6	9 May 2002	1501523	2 Feb 2005
	Hong Kong	05102030.3	9 May 2002	1072179	19 Aug 2005
	Indonesia	W-00200402756	9 May 2002	043.154A	26 May 2005
	India	3493/DELNP/04	9 May 2002	N/A	N/A
	Japan	2004-503016	9 May 2002	2005-523314	27 Oct 2005
	South Korea	10-2004-7018082	9 May 2002	N/A	N/A
	Mexico	PA/2004/011113	9 May 2002	PA/2004/011113	24 May 2005
	Norway	2004 4865	9 May 2002	N/A	N/A
	Philippines	1-2004-501786	9 May 2002	N/A	N/A
	Ukraine	20041210106	9 May 2002	N/A	N/A
	PCT	PCT/US02/14836	9 May 2002	WO 03/094932	20 Nov 2003
	South Africa	2004/9035	9 May 2002	N/A	N/A
3	United States	10/600182	20 June 2003	2004/0131703	8 July 2004
	Australia	2003279236	20 June 2003	N/A	N/A
	Bosnia/ Herzegovina	BAP041915A	20 June 2003	N/A	N/A
	Canada	2490392	20 June 2003	N/A	N/A
	China	03819736.7	20 June 2003	CN 1674942A	
	Serbia/ Montenegro	P-1105/2004	20 June 2003	N/A	N/A
	Eurasia	200500062	20 June 2003	N/A	N/A
	Europe	03742119.5	20 June 2003	1515753	23 Mar 2005
	Croatia	P20041204A	20 June 2003	P20041204A	30 June 2005
	India	4077/DELNP/04	20 June 2003	N/A	N/A
	Japan	2004-516066	20 June 2003	2005-533812	10 Nov 2005
	Mexico	PA/2004/012863	20 June 2003	PA/2004/012863	13 June 2005
	Norway	20050011	20 June 2003	N/A	N/A
	Poland	P-375161	20 June 2003	N/A	N/A
	Ukraine	200500541	20 June 2003	N/A	N/A
	PCT	PCT/US03/19609	20 June 2003	WO 2004/000368	31 Dec 2003
4	United States	10/371666	21 Feb 2003	US 2003/0219497	27 Nov 2003
	Australia	2003216368	21 Feb 2003	N/A	N/A
	Bosnia/ Herzegovina	BAP041840A	21 Feb 2003	N/A	N/A
	Canada	2481972	21 Feb 2003	N/A	N/A
	China	03812662.1	21 Feb 2003	CN 1658889A	24 Aug 2005
	Serbia/ Montenegro	PCT/US03/05428	21 Feb 2003	N/A	N/A
	Eurasia	200401365	21 Feb 2003	N/A	N/A
	Europe	03746917.8	21 Feb 2003	1499333	26 Jan 2005

Licensed From Beth Israel Deaconess Medical Center, et al					
Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue /Pub Date
	Croatia	P20040972A	21 Feb 2003	P20040972A	30 June 2005
	India	3556/DELNP/04	21 Feb 2003	N/A	N/A
	Japan	2003-585676	21 Feb 2003	2005-531534	20 Oct 2005
	Mexico	PA/2004/010243	21 Feb 2003	PA/2004/010243	6 Oct 2005
	Norway	20044562	21 Feb 2003	N/A	N/A
	Poland	P-373002	21 Feb 2003	N/A	N/A
	Ukraine	20041109277	21 Feb 2003	N/A	N/A
	PCT	PCT/US03/05428	21 Feb 2003	WO 03/088923	30 Oct 2003
5	United States	10/413817	15 April 2003	2004/0005367	8 Jan 2004
	Australia	2003223562	15 April 2003	N/A	N/A
	Bosnia/ Herzegovina	BAP041839A	15 April 2003	N/A	N/A
	Canada	2481786	15 April 2003	N/A	N/A
	China	03811310.4	15 April 2003	CN 1652802A	10 Aug 2005
	Serbia/ Montenegro	P-911/2004	15 April 2003	N/A	N/A
	Eurasia	200401366	15 April 2003	N/A	N/A
	Europe	03719698.7	15 April 2003	1499328	26 Jan 2005
	Croatia	P20040973A	15 April 2003	P20040973A	30 June 2005
	India	3548/DELNP/04	15 April 2003	N/A	N/A
	Japan	2003-585733	15 April 2003	2005-530737	13 Oct 2005
	Mexico	PA/2004/010242	15 April 2003	PA/2004/010242	10 Aug 2005
	Norway	2004 4564	15 April 2003	N/A	N/A
	Poland	P-374241	15 April 2003	N/A	N/A
	Ukraine	20041109278	15 April 2003	N/A	N/A
	PCT	PCT/US03/11167	15 April 2003	WO 03/088981	30 Oct 2003
6	United States	10/367277	13 Feb 2003	2003/0219496	27 Nov 2003
	Australia	2003211102	13 Feb 2003	N/A	N/A
	Bosnia/ Herzegovina	BAP041790A	13 Feb 2003	N/A	N/A
	Brazil	PI0307673-3	13 Feb 2003	N/A	N/A
	Canada	2475963	13 Feb 2003	N/A	N/A
	China	03808352.3	13 Feb 2003	CN 1646146A	27 July 2005
	Columbia	04084713	13 Feb 2003	1156	28 Feb 2006
	Eurasia	200401070	13 Feb 2003	200401070	24 Feb 2005
	Europe	03743140.0	13 Feb 2003	1480658	1 Dec 2004
	Hong Kong	04110032.5	13 Feb 2003	1069761	3 June 2005
	Indonesia	W-00200401738	13 Feb 2003	W-00200401738	8 Sep 2005
	India	2348/DELNP/04	13 Feb 2003	N/A	N/A
	Japan	2003-570771	13 Feb 2003	2005-525848	2 Sep 2005
	South Korea	10-2004-7012581	13 Feb 2003	N/A	N/A
	Mexico	PA/2004/007896	13 Feb 2003	PA/2004/007896	6 Oct 2005

Licensed From Beth Israel Deaconess Medical Center, et al					
Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue /Pub Date
	Norway	2003 4590	13 Feb 2003	N/A	N/A
	Philippines	1-2004-501224	13 Feb 2003	N/A	N/A
	Singapore	200306034-0	13 Feb 2003	N/A	N/A
	Singapore	200605472-0	11 Aug 2006	N/A	N/A
	Ukraine	20040907416	13 Feb 2003	N/A	N/A
	PCT	PCT/US03/04665	13 Feb 2003	WO 03/072024	4 Sep 2003
	South Africa	2004/6398	13 Feb 2003	N/A	N/A
7	United States	10/455564	5 June 2003	2004/0258772	23 Dec 2004
	Australia	2003248621	5 June 2003	N/A	N/A
	Bosnia/ Herzegovina	BAP041898A	5 June 2003	N/A	N/A
	Canada	2487413	5 June 2003	N/A	N/A
	China	0318872.4	5 June 2003	CN 1674922A	28 Sep 2005
	Serbia/ Montenegro	P-1053/2004	5 June 2003	N/A	N/A
	Eurasia	200401622	5 June 2003	N/A	N/A
	Europe	03757348.2	5 June 2003	1509237	2 Mar 2005
	Croatia	P20041146A	5 June 2003	P20041146A	30 June 2005
	India	3818/DELNP/04	5 June 2003	N/A	N/A
	Japan	2004-510706	5 June 2003	2005-532351	27 Oct 2005
	Mexico	PA/2004/012167	5 June 2003	PA/2004/012167	2 Dec 2005
	Norway	2004 5354	5 June 2003	N/A	N/A
	Poland	P374375	5 June 2003	N/A	N/A
	Ukraine	200500061	5 June 2003	N/A	N/A
	PCT	PCT/US03/17731	5 June 2003	WO 03/103585	18 Dec 2003
8	United States	10/439632	16 May 2003	2004/0052866	18 Mar 2004
	Australia	2003234585	16 May 2003	N/A	N/A
	Bosnia/ Herzegovina	BAP041868A	16 May 2003	N/A	N/A
	Canada	2485465	16 May 2003	N/A	N/A
	China	0381623.3	16 May 2003	CN 1668314A	14 Sep 2005
	Serbia/ Montenegro	P-993/2004	16 May 2003	N/A	N/A
	Eurasia	200401525	16 May 2003	N/A	N/A
	Europe	03728926.1	16 May 2003	1505990	16 Feb 2005
	Croatia	P20041071A	16 May 2003	P20041071A	30 June 2005
	India	3596/DELNP/04	16 May 2003	N/A	N/A
	Japan	2004-504976	16 May 2003	2005-533021	4 Nov 2005
	Mexico	PA/2004/011426	16 May 2003	PA/2004/011426	11 Nov 2005
	Norway	2004 5056	16 May 2003	N/A	N/A
	Poland	P374177	16 May 2003	N/A	N/A
	Ukraine	20041210382	16 May 2003	N/A	N/A

Licensed From Beth Israel Deaconess Medical Center, et al					
Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue /Pub Date
	PCT	PCT/US03/15263	16 May 2003	WO 03/096977	27 Nov 2003
9	United States	10/676280	30 Sep 2003	2004/0228930	18 Nov 2004
	Australia	2003283982	30 Sep 2003	N/A	N/A
	Bosnia/ Herzegovina	BAP052056A	30 Sep 2003	N/A	N/A
	Canada	2504604	30 Sep 2003	N/A	N/A
	China	03825772.6	30 Sep 2003	CN 1719975A	17 Jan 2006
	Serbia/ Montenegro	P-344/2005	30 Sep 2003	N/A	N/A
	Eurasia	200500782	30 Sep 2003	N/A	N/A
	Europe	03776209.3	30 Sep 2003	1558084	3 Aug 2005
	Croatia	P20050389A	30 Sep 2003	P20050389A	31 Aug 2005
	India	1744/DELNP/05	30 Sep 2003	N/A	N/A
	Japan	2004-551490	30 Sep 2003	2006-514621	11 May 2006
	Mexico	PA/2005/004924	30 Sep 2003	N/A	N/A
	Norway	2005 2348	30 Sep 2003	N/A	N/A
	Poland	P-377733	30 Sep 2003	N/A	N/A
	Ukraine	200505383	30 Sep 2003	N/A	N/A
	PCT	PCT/US03/30956	30 Sep 2003	WO 04/043341	27 May 2004

Licensed From Brigham and Woman's Hospital					
Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue/ Pub Date
1	United States	199343653	06 April 1993	5,427,797	27 June 2005
	Canada	2159915	31 Mar 1994	2159915	08 Jan 2002
	Japan	1994522387	31 Mar 1994	3779726	31 May 2006
	Australia	199464968	31 Mar 1994	690109	23 April 1998
	Europe	1994912377	31 Mar 1994	0692984	24 Jan 1996
	Germany	69428351	31 Mar 1994	69428351	25 Nov 2001
	WO	1994 US3561	31 Mar 1994	1994022499	13 Jan 1994

Licensed From Columbia University					
Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue / Pub Date
1	United States	10/679135	3 Oct. 2003	2005/0048133	3 Mar. 2005
	Canada	2266640	25 Sep. 1997	2266640	2 April 1998
	Mexico			992996	
	Europe	97944453.6	25 Sep. 1997	0951292	27 Oct. 1999
	Japan	0515905	25 Sep. 1997	200159612	6 Feb. 2001

Licensed From General Hospital Corporation					
Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue / Pub Date
1	United States*	09/605,900	28 June 2000	6,601,580	5 Aug 2003
	United States*	10/458,578	28 June 2003	6,935,334	30 Aug 2005

Licensed From General Hospital Corporation					
Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue / Pub Date
	Australia	2001273622	22 June 2001	N/A	N/A
	Canada	2414409	22 June 2001	N/A	N/A
	China	01811886.0	22 June 2001	1635923	06 July 2005
	Hong Kong	03106054.7	22 June 2001	N/A	N/A
	Israel	153702	22 June 2001	N/A	N/A
	Japan	2002-504958	22 June 2001	2004509850	02 April 2004
	South Korea	2002-7017893	22 June 2001	2003029530	14 April 2003
	Mexico	PA/2003/00018 2	22 June 2001	2003000182	01 March 2004
	Singapore	200207814-5	22 June 2001	N/A	N/A
	PCT *	US01/41102	22 June 2001	WO 2002000175	03 Jan 2002
	South Africa	2003/0702	22 June 2001	2003/0702	29 Sep 2004
	Europe *	01952915.5	22 June 2001	1301076	16 April 2003
2	United States*	60/542,000	4 Feb 2004	N/A	N/A
3	United States*	08/384,792	10 Feb 1995	5,485,827	23 Jan 1996
	United States*	08/036,522	24 Mar 1993	5,536,241	16 July 1996
	United States*	08/353,508	9 Dec 1994	5,873,359	23 Feb 1999
	Australia	91498/91	5 Dec 1991	657726	11 July 1995
	Brazil	PI9302645-5	24 June 1993	PI9302645-5	13 April 2004
	Brazil	PI9307985-0	24 June 1993	N/A	N/A
	Canada	2097823	5 Dec 1991	2097823	29 June 1999
	Chile	708-93	22 June 1993	N/A	N/A
	Chile	2059-2002	22 June 1993	N/A	N/A
	Hong Kong	99105833.2	24 Sep 1998	N/A	N/A
	Japan	4-502844	5 Dec 1991	2701978	3 Oct 1997
	Japan	9-036785	5 Dec 1991	3510755	9 Jan 2004
	Japan	2002-217936	5 Dec 1991	N/A	N/A
	Mexico	933814	24 June 1993	206,992	6 Mar 2002
	Singapore	9602651-3	5 Dec 1991	47527	17 April 2001
	Uruguay	241333	22 Dec 1995	N/A	N/A
	PCT*	US91/09111	5 Dec 1991	WO 1992010228	08 July 1992
	Austria	92902708.4	5 Dec 1991	0560928	24 Sep 1997
	Belgium	92902708.4	5 Dec 1991	0560928	24 Sep 1997
	Switzerland	92902708.4	5 Dec 1991	0560928	24 Sep 1997
	Germany	92902708.4	5 Dec 1991	69127756.7	24 Sep 1997
	Denmark	92902708.4	5 Dec 1991	0560928	24 Sep 1997
	Estonia	P9400192	15 Sep 1994	03119	16 Oct 1998
	Europe*	92902708.4	5 Dec 1991	0560928	24 Sep 1997
	Europe*	97105021.6	5 Dec 1991	786264	13 Aug 1997
	Europe*	1992902708	5 Dec 1991	1516639	23 March 2005
	Spain	92902708.4	5 Dec 1991	0560928	24 Sep 1997
	France	92902708.4	5 Dec 1991	0560928	24 Sep 1997
	United	92902708.4	5 Dec 1991	0560928	24 Sep 1997

Licensed From General Hospital Corporation					
Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue / Pub Date
	Kingdom				
	Hellenic Republic	92902708.4	5 Dec 1991	0560928	24 Sep 1997
	Italy	92902708.4	5 Dec 1991	0560928	24 Sep 1997
	Luxembourg	92902708.4	5 Dec 1991	0560928	24 Sep 1997
	Latvia	P-98-169	24 Aug 1998	12201	20 May 1999
	Monaco	92902708.4	5 Dec 1991	0560928	24 Sep 1997
	Netherlands	92902708.4	5 Dec 1991	0560928	24 Sep 1997
4	United States*	07/850,383	11 Mar 1992	5,396,882	14 Mar 1995
	Brazil	PI9306060-2	8 Mar 1993	PI9306060-2	18 Mar 2003
	Canada	2117691	8 Mar 1993	N/A	N/A
	Chile	259-93	9 Mar 1993	N/A	N/A
	Japan	5-516066	8 Mar 1993	3,573,455	9 July 2004
	Japan	2004-77201	8 Mar 1993	3792701	05 July 2006
	Mexico	93/1357	11 Mar 1993	190474	30 Nov 1998
	Venezuela	65293	13 May 1993	54.726	10 Oct 1995
	PCT *	US93/02518	8 Mar 1993	WO 1993017741	16 Sept 1993
	Austria	93908422.4	8 Mar 1993	E242022	4 June 2003
	Belgium	93908422.4	8 Mar 1993	0630270	4 June 2003
	Switzerland	93908422.4	8 Mar 1993	0630270	4 June 2003
	Germany	93908422.4	8 Mar 1993	69333015.5	4 June 2003
	Denmark	93908422.4	8 Mar 1993	0630270	4 June 2003
	Europe*	93908422.4	8 Mar 1993	0630270	4 June 2003
	Spain	93908422.4	8 Mar 1993	0630270	4 June 2003
	Finland	944170	8 Mar 1993	110922	30 April 2003
	France	93908422.4	8 Mar 1993	0630270	4 June 2003
	United Kingdom	93908422.4	8 Mar 1993	0630270	4 June 2003
	Hellenic Republic	93908422.4	8 Mar 1993	0630270	4 June 2003
	Ireland	93908422.4	8 Mar 1993	0630270	4 June 2003
	Italy	93908422.4	8 Mar 1993	0630270	4 June 2003
	Liechtenstein	93908422.4	8 Mar 1993	0630270	4 June 2003
	Luxembourg	93908422.4	8 Mar 1993	0630270	4 June 2003
	Netherlands	93908422.4	8 Mar 1993	0630270	4 June 2003
	Norway	943349	8 Mar 1993	310.961	24 Sep 2001
	Portugal	93908422.4	8 Mar 1993	0630270	4 June 2003
	Sweden	93908422.4	8 Mar 1993	0630270	4 June 2003
5	United States*	08/389,304	16 Feb 1995	6,063,407	16 May 2000
	United States*	08/785,529	17 Jan 1997	5,904,938	18 May 1999
	Argentina	P960101393	15 Feb 1996	N/A	N/A
	Australia	47775/96	8 Feb 1996	690425	6 Aug 1998
	Canada	2213188	8 Feb 1996	N/A	N/A

Licensed From General Hospital Corporation					
Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue / Pub Date
	Chile	207-96	13 Feb 1996	N/A	N/A
	China	96191929.9	8 Feb 1996	1174513	1174513
	Czech Republic	PV2598-97	8 Feb 1996	289677	15 Jan 2002
	Japan	8-525022	8 Feb 1996	11500125	06 Jan 1999
	South Korea	97-705582	8 Feb 1996	0426528	29 Mar 2004
	Mexico	976257	8 Feb 1996	198,771	25 Sep 2000
	Singapore	9704917-5	8 Feb 1996	45941	30 Mar 1999
	Venezuela	233-96	14 Feb 1996	57.492	14 Feb 1996
	PCT *	US96/01745	8 Feb 1996	1996025184	22 Aug 1996
	South Africa	96/1183	14 Feb 1996	96/1183	26 Feb 1997
	Europe*	96903806.6	8 Feb 1996	810884	10 Dec 1997
	Finland	973357	8 Feb 1996	N/A	N/A
	Hungary	P9802093	8 Feb 1996	199802093	28 June 2000
	Norway	97.3768	8 Feb 1996	315355	25 Aug 2003
6	United States*	08/222,256	1 April 994	5,570,683	5 Nov 1996
	United States*	08/718,349	7 Jan 1997	5,823,180	20 Oct 1998
	Australia	22058/95	3 April 1995	688027	2 July 1998
	Canada	2186892	3 April 1995	N/A	N/A
	Japan	7-525910	3 April 1995	9512523	16 Dec 1997
	South Korea	96-705567	3 April 1995	0371082	22 Jan 2003
	PCT *	US95/04123	3 April 1995	WO 1995026768	12 Oct 1995
	Austria	95915014.5	3 April 1995	0754069	23 June 2004
	Belgium	95915014.5	3 April 1995	0754069	23 June 2004
	Switzerland	95915014.5	3 April 1995	0754069	23 June 2004
	Germany	95915014.5	3 April 1995	0754069	23 June 2004
	Denmark	95915014.5	3 April 1995	0754069	23 June 2004
	Europe*	95915014.5	3 April 1995	0754069	23 June 2004
	Europe*	04013974.3	15 June 2004	1466641	13 Oct 2004
	Spain	95915014.5	3 April 1995	0754069	23 June 2004
	France	95915014.5	3 April 1995	0754069	23 June 2004
	United Kingdom	95915014.5	3 April 1995	0754069	23 June 2004
	Ireland	95915014.5	3 April 1995	0754069	23 June 2004
	Italy	95915014.5	3 April 1995	0754069	23 June 2004
	Luxembourg	95915014.5	3 April 1995	0754069	23 June 2004
	Netherlands	95915014.5	3 April 1995	0754069	23 June 2004
	Sweden	95915014.5	3 April 1995	0754069	23 June 2004
7	United States*	08/832,913	4 April 1997	5,885,621	23 Feb 1999
	ARIPO	AP/P98/01358	3 April 1997	AP 897	30 Nov 2000
	Australia	24403/97	3 April 1997	720686	21 Sep 2000
	Brazil	PI9708601-0	3 April 1997	N/A	N/A
	Canada	2251530	3 April 1997	2251530	19 Nov 2002

Licensed From General Hospital Corporation					
Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue / Pub Date
	Chile	624-97	4 April 1997	N/A	N/A
	China	97195306.6	3 April 1997	1227485	01 Sept 1999
	Japan	09-536357	3 April 1997	200510448	15 Aug 2000
	Mexico	988195	3 April 1997	206,840	22 Feb 2002
	OAPI	9800189	3 April 1997	10893	7 Oct 1999
	PCT*	US97/05633	3 April 1997	WO199724403	16 Oct 1997
	Europe*	97920137.3	3 April 1997	1712226	18 Oct 2006
8	United States*	08/971,003	14 Nov 1997	6,656,452	2 Dec 2003
	United States*	10/694,490	27 Oct 2003	6,811,768	2 Nov 2004
	Argentina	P980105231	20 Oct 1998	N/A	N/A
	Australia	11012/99	19 Oct 1998	751853	19 Dec 2002
	Canada	2309038	19 Oct 1998	N/A	N/A
	Japan	2000-516651	19 Oct 1998	2003532615	05 Nov 2003
	PCT *	US98/22044	19 Oct 1998	WO 1999020251	29 April 1999
	South Africa	98/9550	20 Oct 1998	98/9550	29 Sep 1999
	Europe*	98953702.2	19 Oct 1998	N/A	N/A

* Any patents or applications that claim priority to any of the United States, Europe, or PCT applications that are listed are intended to be included.

C. Ikaria Research, Inc.

Patents and Patent Applications owned by Research:

Title	Filing Date	Type	Number
Compositions and Methods of Enhancing Survivability and Reducing Injury of Cells, Tissues, Organs and Organisms under Hypoxic or Ischemic Conditions	March 10, 2006	Provisional (P1)	60/781,036
Compositions and Methods of Enhancing Survivability and Reducing Injury of Cells, Tissues, Organs and Organisms under Hypoxic or Ischemic Conditions	March 17, 2006	Provisional (P2)	60/783,450
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2006	Filed Provisional (P1)	60/849,900
Compositions and Methods of Enhancing Survivability and Reducing Injury of Cells, Tissues, Organs, and Organisms Under Ischemic or Hypoxic Conditions	December 6, 2006	Filed Provisional	60/868,778
Combinations of Nitric Oxide and Sulfide and Methods of Use and Manufacture Thereof	December 22, 2006	Filed Provisional	60/877,051
Methods, Compositions and Articles of Manufacture for Enhancing Survivability of Cells, Tissues, Organs,	January 18, 2007	Filed Provisional	60/885,619

and Organisms			
Liquid Chalcogenide Compositions and Manufacturing Using the Same	March 23, 2007	Filed Provisional (P2)	60/896,727
Compositions and Methods of Enhancing Survivability and Reducing Injury of Cells, Tissues, Organs, and Organisms Under Ischemic or Hypoxic Conditions	March 12, 2007	US Utility	11/684,968
Compositions and Methods to Modulate Angiogenesis	June 15, 2007	Filed Provisional	60/944,444
Compositions and Methods to Modulate Angiogenesis	June 15, 2008	US Utility	12/664,872
Compositions and Methods to Modulate Angiogenesis	June 15, 2008	PCT	PCT/US2008/066973
Combinations of Nitric Oxide and Sulfide and Methods of Use and Manufacture Thereof	December 20, 2007	PCT	PCT/US2007/088402
Combinations of Nitric Oxide and Sulfide and Methods of Use and Manufacture Thereof	December 20, 2007	US Utility	12/520,772
Compositions Comprising Sulfide Alone or In Combination With Nitric Oxide and Their Use	June 13, 2008	Japanese National Phase of PCT US08/066973	010-512395
Combinations of Nitric Oxide and Sulfide and Methods of Use and Manufacture Thereof	June 13, 2008	European National Phase of PCT US08/066973	8771066.1
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	US Utility	12/023,840
Compositions and Methods to Modulate Angiogenesis	June 15, 2008	PCT	PCT/US/08/066973
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Singapore National Phase of PCT (WO2008/043081)	200901916-7
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	New Zealand National Phase of PCT (WO2008/043081)	575671
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Canadian National Phase of PCT (WO2008/043081)	2,664,341
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Australian National Phase of PCT (WO2008/043081)	2007303050
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	European National Phase of PCT (WO2008/043081)	078553810.5
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Brazilian National Phase of PCT (WO2008/043081)	496109

Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Indonesia National Phase of PCT (WO2008/043081)	W- 00200900884
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Japanese National Phase of PCT (WO2008/043081)	2009-531630
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Israel National Phase of PCT (WO2008/043081)	197945
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Mexican National Phase of PCT (WO2008/043081)	MX/A/2009/0 03741
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Indian National Phase of PCT (WO2008/043081)	2741/DELNP/ 2009
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	South Korean National Phase of PCT (WO2008/043081)	10-2009- 7009278
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Chinese National Phase of PCT (WO2008/043081)	20078004115 7.7
Liquid Chalcogenide Compositions and Manufacturing Using the Same	October 5, 2007	Hong Kong	09110449.7
Methods for Treating or Preventing Radiocontrast Agent Induced Kidney Injury	January 21, 2010	US Utility	12/690,368
Methods for Treating or Preventing Radiocontrast Agent Induced Kidney Injury	January 21, 2010	PCT	PCT/US10/215 62
Compositions and Methods for Treating or Preventing Hypoxic or Ischemic Injury	October 16, 2008	Provisional	61/146,222
Compositions and Methods for Treating or Preventing Hypoxic or Ischemic Injury	October 16, 2009	PCT	PCT/US2009/ 061046
Compositions and Methods for Treating or Preventing Hypoxic or Ischemic Injury	October 16, 2009	US Utility	12/580,458
Compositions and Methods for Treating or Preventing Hypoxic or Ischemic Injury	Feb. 11, 2010	Provisional	61/303,532
Process for the Manufacture of High Purity Carbon Monoxide	March 3, 2010	Provisional	61/309,973
Methods of Treating Term and Near-Term Neonates Having Hypoxic Respiratory Failure Associated with Clinical or Echocardiographic Evidence	June 30, 2009	US Utility	12/494,598

of Pulmonary Hypertension			
Methods of Treating Term and Near-Term Neonates Having Hypoxic Respiratory Failure Associated with Clinical or Echocardiographic Evidence of Pulmonary Hypertension	June 30, 2009	Australia	2009202685
Methods of Treating Term and Near-Term Neonates Having Hypoxic Respiratory Failure Associated with Clinical or Echocardiographic Evidence of Pulmonary Hypertension	June 30, 2009	Canada	2671029
Methods of Treating Term and Near-Term Neonates Having Hypoxic Respiratory Failure Associated with Clinical or Echocardiographic Evidence of Pulmonary Hypertension	June 30, 2009	Japan	2009-157623
Methods of Treating Term and Near-Term Neonates Having Hypoxic Respiratory Failure Associated with Clinical or Echocardiographic Evidence of Pulmonary Hypertension	June 30, 2009	Europe	09251949.5
Methods of Treating Term and Near-Term Neonates Having Hypoxic Respiratory Failure Associated with Clinical or Echocardiographic Evidence of Pulmonary Hypertension	June 30, 2009	Mexico	N/A
Devices and Methods for Engaging Indexed Valve and Pressurized Canister Assembly with Collar and for Linear Actuation by Plunger Assembly into Fluid Communication	June 27, 2009	PCT	PCT/US2009/4526

(a) In-Licenses of Patents and Patent Applications

Research in-licenses the following patents and patent applications:

Title	Filing Date	Type	Number
Methods for Inducing Reversible Stasis	June 11, 2001	Provisional	60/297,607
Methods for Inducing Reversible Stasis	June 10, 2002	Published PCT	WO 02/101018
Methods for Inducing Reversible Stasis	October 22, 2004	US Utility	10/480,430
Methods for Apparatuses for Preserving Live Cells, Tissues and Organs	October 22, 2003	Provisional	60/513,458
Methods and Apparati for Induction of Stasis in Cells, Tissues, Organs and Organisms	February 26, 2004	Provisional	60/548,150
Methods for Apparatuses for Preserving Live Cells, Tissues and Organs	June 8, 2004	Provisional	60/577,942
Methods, Compositions and Articles of Manufacture for Treating Shock and Other Adverse Conditions	December 7, 2006	Provisional Application	60/869,054
Methods, Compositions and Devices for Inducing Stasis in Cells	October 22, 2004	Published PCT	WO/2005/039291

Methods, Compositions and Devices for Inducing Stasis in Cells	October 22, 2004	Australian National Phase of PCT (WO/2005/039 291)	2004283729
Methods, Compositions and Devices for Inducing Stasis in Cells	October 22, 2004	Canadian National Phase of PCT (WO/2005/039 291)	2,542,426
Methods, Compositions and Devices for Inducing Stasis in Cells	October 22, 2004	European National Phase of PCT (WO/2005/039 291)	04796300.4
Methods, Compositions and Devices for Inducing Stasis in Cells	October 22, 2004	Japanese National Phase of PCT (WO/2005/039 291)	2006-536886
Methods, Compositions and Devices for Inducing Stasis in Cells	October 22, 2004	US Utility	10/971,576
Methods, Compositions and Devices for Inducing Stasis in Tissues and Organs	October 22, 2004	Published PCT	WO/2005/041656
Methods, Compositions and Devices for Inducing Stasis in Cells	October 22, 2004	Australian National Phase of PCT (WO/2005/041 656)	2004285477
Methods, Compositions and Devices for Inducing Stasis in Cells	October 22, 2004	Canadian National Phase of PCT (WO/2005/041 656)	2,542,810
Methods, Compositions and Devices for Inducing Stasis in Cells	October 22, 2004	European National Phase of PCT (WO/2005/041 656)	04796091.9
Methods, Compositions and Devices for Inducing Stasis in Cells	October 22, 2004	Japanese National Phase of PCT (WO/2005/041 656)	2006-536822
Methods, Compositions and Devices for Inducing Stasis in Tissues and Organs	October 22, 2004	US Utility	10/972,063
Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs and Organisms	October 22, 2004	Published PCT	WO/2005/041655
Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs and Organisms	October 22, 2004	Australian National Phase of PCT (WO/2005/041 655)	2004285468

Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs and Organisms	October 22, 2004	Canadian National Phase of PCT (WO/2005/041 655)	2,542,806
Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs and Organisms	October 22, 2004	European National Phase of PCT (WO/2005/041 655)	04796043.0
Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs and Organisms	October 22, 2004	Japanese National Phase of PCT (WO/2005/041 655)	2006-536810
Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs and Organisms	October 22, 2004	Brazilian National Phase of PCT (WO/2005/041 655)	PI0415752-4
Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs and Organisms	October 22, 2004	Chinese National Phase of PCT (WO/2005/041 655)	200480036061.8
Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs and Organisms	December 5, 2006	Hong Kong National Phase of PCT (WO/2005/041 655) from EP	06 113365.4
Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs and Organisms	October 22, 2004	Mexican National Phase of PCT (WO/2005/041 655)	PA/A/2006/00452 7
Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs and Organisms	October 22, 2004	US Utility	10/971,575
Methods, Compositions and Articles of Manufacture for Enhancing Survivability of Cells, Tissues, Organs and Organisms	April 20, 2005	Provisional (P1)	60/673,037
Methods, Compositions and Articles of Manufacture for Increasing Survivability of Cells, Tissues, Organs and Organisms	April 20, 2005	Provisional (P2)	60/673,295
Methods, Compositions and Articles of Manufacture for Enhancing Survivability of Cells, Tissues, Organs and Organisms	August 31, 2005	Provisional (P3)	60/713,073
Methods, Compositions and Articles of Manufacture for Enhancing Survivability of Cells, Tissues, Organs and Organisms	October 28, 2005	Provisional (P4)	60/731,549

Methods, Compositions and Articles of Manufacture for Enhancing Survivability of Cells, Tissues, Organs and Organisms	January 26, 2006	Provisional (P5)	60/762,462
Methods, Compositions and Articles of Manufacture for Enhancing Survivability of Cells, Tissues, Organs and Organisms	April 20, 2006	US Utility	11/408,734
Methods, Compositions and Articles of Manufacture for Enhancing Survivability of Cells, Tissues, Organs and Organisms	April 20, 2006	PCT	WO/2006/113914
Methods, Compositions and Articles of Manufacture for Treating Shock	April 20, 2006	Filed Provisional	60/793,520
Methods, Compositions and Articles of Manufacture for Hif Modulating Compounds	September 28, 2006	Filed Provisional	60/827,337
Compositions and Methods of Enhancing Survivability and Reducing Injury of Cells, Tissues, Organs, and Organisms Under Ischemic or Hypoxic Conditions	December 6, 2006	Filed Provisional	60/868,778
Combinations of Nitric Oxide and Sulfide and Methods of Use and Manufacture Thereof	December 22, 2006	Filed Provisional	60/877,051
Methods, Compositions and Articles of Manufacture for Enhancing Survivability of Cells, Tissues, and Organisms	January 18, 2007	Filed Provisional	60/885,619
Thyronamine Derivatives and Analogs and Methods of Use Thereof	April 18, 2003	Issued Patent 6,979,750 (Issue Date 12/27/05)	10/418,399
Thyronamine Derivatives and Analogs and Methods of Use Thereof	April 16, 2004	Filed Continuation in Part (Parent 10/418,399)	10/825,881
Thyronamine Derivatives and Analogs and Methods of Use Thereof	April 5, 2005	Filed Continuation in Part (Parent 10/825,881)	11/099,959
Thyronamine Derivatives and Analogs and Methods of Use Thereof	June 17, 2005	Filed Divisional (Parent 10/418,399)	11/155,345
Thyronamine Derivatives and Analogs and Methods of Use Thereof	April 19, 2004	Filed PCT (Continuation of 10/825,881)	WO/2004/93800
Thyronamine Derivatives and Analogs and Methods of Use Thereof	April 19, 2004	Australian National Phase of PCT (WO/2004/93800)	200423199

Thyronamine Derivatives and Analogs and Methods of Use Thereof	April 19, 2004	Japanese National Phase of PCT (WO/2004/938 00)	2006-513091
Thyronamine Derivatives and Analogs and Methods of Use Thereof	April 19, 2004	Canadian National Phase of PCT (WO/2004/938 00)	2,517,560
Thyronamine Derivatives and Analogs and Methods of Use Thereof	April 19, 2004	European National Phase of PCT (WO/2004/938 00)	04759961.8

Family	Country	Serial No.	Filing Date	Patent or Pub. No.	Issue / Pub Date
1	United States	09/084,724	26 May 1998	6,089,229	18 July 2000
	Europe	99 303974.2	25 May 1999	0960629	23 Aug 2000
	Germany	1999/6026686	21 May 1999	69926686	22 Sep 2005
	Spain	1999/0303974	21 May 1999	2245076	16 Dec 2005
	Canada	2272002	17 May 1999	2272002	26 Nov 1999
2	United States	09/025,382	18 Feb 1998	6,109,260	29 Aug 2000
	Europe	99 301179.0	17 Feb 1999	0937479	25 Aug 1999
	Austria	1999/0301179	17 Feb 1999	315947	15 Feb 2006
	Germany	1999/6029495	17 Feb 1999	69929495	6 April 2006
3	United States	08/857,925	16 May 1997	6,125,846	3 Oct 2000
	Europe	98 303849.8	15 May 1998	0879612	25 Nov 1998
	Germany	1998/6030021	15 May 1998	69830021	9 June 2005
	Spain	1998/0303849	15 May 1998	2242260	1 Nov 2005
4	United States	09/084,710	26 May 1998	6,164,276	26 Dec 2000
	Europe	99 304104.5	26 May 1999	0960630	12 Jan 1999
	Germany	1999/6025957	26 May 1999	69925957	4 Aug 2005
	Spain	1999/0304104	26 May 1999	2244149	1 Dec 2005
5	United States	09/598,584	21 June 2000	6,581,592	24 June 2003
6	Europe	98 303848.0	15 May 1998	0878208	25 Aug 1999
	Germany	1998/6028328	15 May 1998	69828218	22 Dec 2005
	Spain	1998/0303848	15 May 1998	2232916	1 June 2005
7	United States	11/355670		N/A	N/A
8	United States	11/231554		N/A	N/A
9	United States	60/778075		N/A	N/A
10	United States	10/780161	17 Feb 2004	6962154	08 Nov 2005
	Germany	10306766	18 Feb 2003	10306766	26 Aug 2004
	Canada	2457679	13 Feb 2004	2457679	18 Aug 2004
	Europe	20042347	03 Feb 2004	1449559	25 Aug 2004

(D) **Ikaria Development Subsidiary One LLC**

(a) Patents in-licensed by Ikaria Development Subsidiary One LLC.

(i) *U.S. Patents/Patent applications*

<u>In-license from Bioline</u>			
<u>Title</u>	<u>Filing Date</u>	<u>Type</u>	<u>Number</u>
Injectable Cross-Linked Polymeric Preparations And Uses Thereof	September 19, 2005	US Utility	11/229,119
Injectable Cross-Linked Polymeric Preparations And Uses Thereof	December 24, 2009	US Utility	12/647,280
Injectable Cross-Linked Polymeric Preparations And Uses Thereof	December 24, 2009	US Utility	12/647,295
Injectable Cross-Linked Polymeric Preparations And Uses Thereof	December 24, 2009	US Utility	12/647,257

(ii) *Non-U.S. Patents/Patent applications*

<u>Title</u>	<u>Filing Date</u>	<u>Type</u>	<u>Number</u>
A Method Of Promoting Tissue Repair	March 13, 2008	Australian National Phase of PCT (WO/2008/111074)	2008224436
A Method Of Promoting Tissue Repair	March 13, 2008	Chinese National Phase of PCT (WO/2008/111074)	20088001428 0.4
A Method Of Promoting Tissue Repair	March 13, 2008	European National Phase of PCT (WO/2008/111074)	08719973.3
A Method Of Promoting Tissue Repair	March 13, 2008	Indian National Phase of PCT (WO/2008/111074)	6041/CHENP/ 2009
A Method Of Promoting Tissue Repair	March 13, 2008	Israel National Phase of PCT (WO/2008/111074)	200838
A Method Of Promoting Tissue Repair	March 13, 2008	Japanese National Phase of PCT (WO/2008/111074)	2009-553279
A Method Of Promoting Tissue Repair	March 13, 2008	South Korean National Phase of PCT (WO/2008/111074)	10-2009- 7019708
A Method Of Promoting Tissue Repair	March 13, 2008	Canadian National Phase of PCT (WO/2008/111074)	2,680,230
A Method Of Promoting Tissue Repair	March 13, 2008	Mexican National Phase of PCT (WO/2008/111074)	MX/a/2009/0 09710
Method Of Promoting Tissue Repair	September 9, 2009	US Utility	12/530,488
Injectable Cross-Linked Polymeric Preparations And Uses Thereof	May 4, 2004	Australian National Phase of PCT (WO/2004/098669)	2005211584

Injectable Cross-Linked Polymeric Preparations And Uses Thereof	May 4, 2004	Canadian National Phase of PCT (WO/2004/098669)	2,524,356
Injectable Cross-Linked Polymeric Preparations And Uses Thereof	May 4, 2004	Chinese National Phase of PCT (WO/2004/098669)	20048001920 1.0
Injectable Cross-Linked Polymeric Preparations And Uses Thereof	May 4, 2004	European National Phase of PCT (WO/2004/098669)	4731094.1
Injectable Cross-Linked Polymeric Preparations And Uses Thereof	May 4, 2004	Indian National Phase of PCT (WO/2004/098669)	3262/CHENP/ 2005
Injectable Cross-Linked Polymeric Preparations And Uses Thereof	May 4, 2004	Indian National Phase of PCT (WO/2004/098669)	626/CHENP/2 005
Injectable Cross-Linked Polymeric Preparations And Uses Thereof	May 4, 2004	Israel National Phase of PCT (WO/2004/098669)	170952
Injectable Cross-Linked Polymeric Preparations And Uses Thereof	May 4, 2004	Japanese National Phase of PCT (WO/2004/098669)	2006-507619
Injectable Cross-Linked Polymeric Preparations And Uses Thereof	May 4, 2004	Mexican National Phase of PCT (WO/2004/098669)	PA/a/2005/01 1896
Injectable Cross-Linked Polymeric Preparations And Uses Thereof	May 4, 2004	South Korean National Phase of PCT (WO/2004/098669)	10-2005- 7020917

(E) Ikaria Development Subsidiary Two LLC

(a) Patents in-licensed by Ikaria Development Subsidiary Two LLC.

(i) *U.S. Patents/Patent Applications*

<u>In-licensed from Fibrex</u>			
<u>Title</u>	<u>Filing Date</u>	<u>Type</u>	<u>Number</u>
Therapeutic Fibrin-Derived Peptides And Uses Thereof	June 11, 2003	US Utility	7,271,144
Therapeutic Fibrin-Derived Peptides And Uses Thereof	October 6, 2006	US Utility	7,494,973
Therapeutic Fibrin-Derived Peptides And Uses Thereof	September 6, 2007	US Utility	111/899,611
Therapeutic Fibrin-Derived Peptides And Uses Thereof	October 9, 2008	US Utility	2.248,656
Pharmaceutical Preparation For The Treatment Of Shock	May 30, 2006	US Utility	10/596,103
Pharmaceutical Preparation For The Treatment Of Hemorrhagic Shock and the Sequels Thereof	June 20, 2008	US Utility	12/158,670
Peptides And Peptide Derivatives As Well As Pharmaceutical Compositions	February 23, 2007	US Utility	11/678,535

Containing The Same			
Peptides And Peptide Derivatives As Well As Pharmaceutical Compositions Thereof	August 23, 2007	US Utility	12/534,716
Peptides And Peptide Derivates, The Production Thereof As Well As Their Use For Preparing A Therapeutically And/Or Preventively Active Pharmaceutical Composition	August 23, 2008	US Utility	12/280,544
Methods Of Screening For Compounds Having Anti-Inflammatory Activity	September 24, 2007	US Utility	11/860,488
Peptides, Peptidomimetics And Derivatives Thereof, The Manufacturing Thereof As Well As Their Use For Preparing A Therapeutically And/Or Preventively Active Pharmaceutical Composition	May 15, 2008	US Utility	12/121,526
Peptides And Derivatives Thereof, The Manufacturing Thereof As Well As Their Use For Preparing A Therapeutically And/Or Preventively Active Pharmaceutical Composition	May 15, 2008	US Utility	12/121,533
Peptides And Derivatives Thereof, The Manufacturing Thereof As Well As Their Use For Preparing A Therapeutically And/Or Preventively Active Pharmaceutical Composition	May 15, 2008	US Utility	12/121,544
Peptides And Peptidomimetic Compounds, The Manufacturing Thereof As Well As Their Use For Preparing A Therapeutically And/Or Preventively Active Pharmaceutical Composition	September 26, 2008	US Utility	12/239,579
Pharmaceutical Compositions And Methods Of Use For The Prevention And Treatment of Hypoxic Injury	October 15, 2009	US Utility	12/580,049
Compositions And Methods For Using Peptides, Modified Peptides, Peptidomimetics And Fibrin Derivatives	November 13, 2009	Provisional	61/261,050

(ii) *Non-U.S. Patents*

<u>In-licensed from Fibrex</u>			
<u>Title</u>	<u>Filing Date</u>	<u>Type</u>	<u>Number</u>
Therapeutic Fibrin-Derived Peptides And Uses Thereof	December 7, 2001	European National Phase of PCT (AAT2001/00387) Elected States: AL, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LT, LU LV, MC, MK, NL, PT, RO SE, SI, TR, AT	115 865861
Therapeutic Fibrin-Derived Peptides	December 7, 2001	European National	1341819

And Uses Thereof		Phase of PCT (AT01/00387) Elected States: AL, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LT, LU LV, MC,MK, NL,RO, PT, RO SE, SI, TR, AT	
Therapeutic Fibrin-Derived Peptides And Uses Thereof	December 7, 2001	Israel National Phase of PCT (AT01/00387)	
Therapeutic Fibrin-Derived Peptides And Uses Thereof	December 7, 2001 December 7, 2001	Japanese National Phase of PCT (AT01/00387)	
Therapeutic Fibrin-Derived Peptides And Uses Thereof	December 7, 2001	South Korean National Phase of PCT (AT01/00387)	
Therapeutic Fibrin-Derived Peptides And Uses Thereof	December 7, 2001	Canadian National Phase of PCT(AT01/00387)	
Therapeutic Fibrin-Derived Peptides And Uses Thereof	December 7, 2001	Mexican National Phase of PCT (AT01/00387)	
Therapeutic Fibrin-Derived Peptides And Uses Thereof	December 7, 2001	Australian National Phase of PCT (AT01/00387)	
Therapeutic Fibrin-Derived Peptides And Uses Thereof	December 7, 2001	Canadian National Phase of PCT (AT01/00387)	
Therapeutic Fibrin-Derived Peptides And Uses Thereof	December 7, 2001	Chinese National Phase of PCT (AT01/00387)	
Therapeutic Fibrin-Derived Peptides And Uses Thereof	December 7, 2001	European National Phase of PCT ()	
Pharmaceutical Preparation For The Treatment Of Shock	June 24, 2005	European National Phase of PCT (AT2005/000228) Elected States: AL, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LT, LU LV, MC,MK, NL,RO, PT, RO SE, SI, TR, AT	EP 1691827
Peptides And Peptide Derivatives As Well As Pharmaceutical Compositions Containing The Same	June 24, 2005	European National Phase of PCT (AT2005/000228)	EP1692887
Peptides And Peptidomimetic Compounds, The Manufacturing Thereof As Well As Their Use For	August 24, 2009	PCT	PCT/AT2009/000324

Preparing A Therapeutically And/Or Preventively Active Pharmaceutical Composition			
Pharmaceutical Compositions And Methods Of Use For The Prevention And Treatment of Hypoxic Injury	October 15, 2009	PCT	PCT/IB2009/007356

[[3210402]]

RECORDED: 06/25/2010

**PATENT
REEL: 024588 FRAME: 0655**